Hormone replacement therapy in women with epilepsy: A randomized, double-blind, placebo-controlled study

Epilepsia

Volumn 47, Issue 9, 2006, Pages 1447-1451

  Harden, Cynthia L ^a,e   Herzog, Andrew G ^b   Nikolov, Blagovest G ^a   Koppel, Barbara S ^c   Christos, Paul J ^a   Fowler, Kristen ^b   Labar, Douglas R ^a   Hauser, W Allen ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c METROPOLITAN HOSPITAL CENTER   (United States)

^d Columbia University ^*  (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Epilepsy; Hormone replacement therapy; Menopause; Postmenopausal; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; PELVIC DISCOMFORT; PELVIC DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; TREATMENT OUTCOME;

ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EPILEPSY; EPILEPSY, COMPLEX PARTIAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIAZINES;

EID: 33748692764     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00507.x     Document Type: Article

References (20)

1. Burger HG. The endocrinology of the menopause. Maturitas 1996;23:129-136.
2. Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002;52:704-711.
3. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004;56:431-434.
4. Harden CL, Pulver MC, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999;40:1402-1407.
5. Hom AC, Buterbaugh GG. Estrogen alters the acquisition of seizures kindled by repeated amygdala stimulation or pentylenetetrazol administration in ovariectomized female rats. Epilepsia 1986;27:103-108.
6. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002;57:357-384.
7. The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-postmenopausal women: principal results of the Women's Health Initiative randomized, controlled trial. JAMA 2002;288:321-333.
8. Johnson EK, Jones JE, Seidenberg M, et al. The relative impact of anxiety, depression and clinical seizures features on health-related quality of life in epilepsy. Epilepsia 2004;45:544-550.
9. Vickrey BG, Berg AT, Sperling MR, et al. Relationships between seizure severity and health-related quality of life in refractory localization-related epilepsy. Epilepsia 2000;41:760-764.
10. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571.
11. De Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-573.
12. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002;59:251-255.
13. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004;62:292-295.
14. Spritzer PM, Vitola D, Vilodre LC, et al. One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone inwomen with mild to moderate hypertension. Exp Clin Endocrinol Diabetes (Germany) 2003;111:267-273.
15. Giuliani A, Concin H,Wieser F, et al. Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone: effect on postmenopausal symptoms and lipid metabolism [Die Hormonersatztherapie mit einem perkutan wirksamen Oestradiol-Gel und oral verabreichtem mikronisierten Progesteron. Auswirkung auf klimakterische Symptome und den Lipidstoffwechsel.] Wien Klin Wochenschr (Austria) 2000;112:629-633.
16. Frye CA, Rhodes ME, Walf A, et al. Progesterone reduces pentylenetetrazol-induced ictal activity of wild-type mice but not those deficient in type I 5alpha-reductase. Epilepsia 2002;43(suppl 5):14-17.
17. Lonsdale D, Burnham WM. The anticonvulsant effects of progesterone and 5alpha-dihydroprogesterone on amygdala-kindled seizures in rats. Epilepsia 2003;44:1494-1499.
18. Reddy DS, Kim HY, Rogawski MA. Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 2001;42:328-336.
19. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995;45:1660-1662.
20. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 1999;52:1917-1918.